Lite Strategy, Inc. (LITS): Free Cash Flow
-$20.84M
Year ended 2025-06-30
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-06-30 | -$20.84M | n/m | 2025-09-26, From 2024-07-01 |
| 2024-06-30 | -$50.48M | n/m | 2025-09-26, From 2023-07-01 |
| 2023-06-30 | -$52.52M | n/m | 2024-09-19, From 2022-07-01 |
| 2022-06-30 | -$49.23M | n/m | 2023-09-26, From 2021-07-01 |
| 2021-06-30 | -$32.67M | n/m | 2022-09-08, From 2020-07-01 |
| 2020-06-30 | $33.36M | n/m | 2022-09-08, From 2019-07-01 |
| 2019-06-30 | -$29.64M | n/a | 2022-05-23, From 2018-07-01 |
| No annual figure between 2017-06-30 and 2019-06-30. | |||
| 2017-06-30 | $3.44M | n/m | 2019-08-28, From 2016-07-01 |
| 2016-06-30 | -$17.86M | n/m | 2018-08-30, From 2015-07-01 |
| 2015-06-30 | -$28.08M | n/m | 2017-09-05, From 2014-07-01 |
| 2014-06-30 | -$19.50M | n/m | 2016-09-06, From 2013-07-01 |
| 2013-06-30 | -$10.08M | n/a | 2015-09-02, From 2012-07-01 |
| No annual figure between 2011-06-30 and 2013-06-30. | |||
| 2011-06-30 | -$6.55M | n/a | 2012-09-18, From 2010-07-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | 2025-06-30 | -$20.84M | n/m |
| Abbott Laboratories (ABT) | 2025-12-31 | $7.39B | +16.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $12.85B | -7.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $9.07B | -7.7% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $19.70B | -0.7% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $28.84M | +101.3% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $12.36B | -31.7% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | -$15.98M | n/m |
| Procyon Corp (PCYN) | 2024-06-30 | -$125.2K | n/m |
Compare LITS, ABT, BMY, PFE side by side · Screen every company in Pharmaceutical Preparations ↗